Design and Synthesis of Novel KCNQ2 Agonists Based on Molecular Module Assembly

doi:10.6023/cjoc202605010

Chinese Journal of Organic Chemistry

ARTICLE

基于分子模块组装的新型KCNQ2激动剂设计与合成

焦金梦^a,b, 叶潇滢^c,d, 田富云^c,d, 高召兵^c,d, 南发俊^b,e,*, 陈林海^b,e,*

^a安徽中医药大学药学院,安徽合肥,230012;
^b烟台新药创制山东省实验室,中科环渤海药物创新研究院,山东烟台,264100;
^c南京中医药大学新中药学院,江苏南京,210023;
^d中科中山药物创新研究院,广东中山,528400;
^e中国科学院上海药物研究所,上海浦东,201203

收稿日期:2026-07-29 修回日期:2026-08-17
基金资助:
国家科技创新2030重大项目（No. 2021ZD0200900）、国家自然科学基金（No. 22477106）、山东省泰山学者青年专家项目（No. tsqn202408314）及烟台市省级以上领军人才专项资助项目.

Design and Synthesis of Novel KCNQ2 Agonists Based on Molecular Module Assembly

Jinmeng Jiao^a,b, Xiaoying Ye^c,d, Fuyun Tian^c,d, Zhaobing Gao^c,d, Fajun Nan^b,e,*, Linhai Chen^b,e,*

^a School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012;
^b Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264100;
^c School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023;
^d Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400;
^e Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 210023

Received:2026-07-29 Revised:2026-08-17
Contact: *E-mail: fjnan@simm.ac.cn; lhchen@simm.ac.cn
Supported by:
National Science and Technology Innovation 2030 Major Program (2021ZD0200900), the National Natural Science Foundation of China (No. 22477106), the Taishan Scholars Program (No. tsqn202408314), and the Special Foundation of Yantai for Leading Talents above Provincial Level.

1. .pdf(3088KB)

Abstract

In this study, a molecular module assembly strategy was employed for the structural optimization of pynegabine (HN37), a clinical candidate targeting the potassium voltage-gated channel subfamily Q (KCNQ). First, an activity prediction model was established based on multi-conformation molecular docking and multiple linear regression. Simultaneously, a virtual compound library with high synthetic accessibility and structural novelty was constructed via modular assembly based on the Buchwald-Hartwig reaction, utilizing diverse building blocks acquired through substructure searches. Subsequently, a hierarchical virtual screening workflow—combining drug-likeness evaluation and established activity prediction model—was applied to identify a set of prioritized structures. On this basis, 24 target compounds were synthesized and evaluated using whole-cell patch-clamp electrophysiology. Experimental results demonstrated that 6 compounds exhibited significant agonistic activity against the KCNQ2 channel at 100 nM, with the structure-activity relationships (SAR) preliminary elucidated. Among them, compounds 3 and 4 showed favorable KCNQ2 agonistic activity, subtype selectivity for KCNQ channels, and metabolic stability. By integrating module-assembly-based molecular design, hierarchical virtual screening, and experimental validation, this work identifies a series of promising KCNQ2 agonists and paves the way for subsequent optimization.

Key words: KCNQ2 agonists, pynegabine, structural optimization, activity-prediction model, molecular module assembly

Cite this article

Jinmeng Jiao, Xiaoying Ye, Fuyun Tian, Zhaobing Gao, Fajun Nan, Linhai Chen. Design and Synthesis of Novel KCNQ2 Agonists Based on Molecular Module Assembly[J]. Chinese Journal of Organic Chemistry, doi: 10.6023/cjoc202605010.

Export EndNote|Reference Manager|ProCite|BibTeX|RefWorks

share this article

References

[1] Fisher R. S.; Van Emde Boas W.; Blume W.; Elger C.; Genton P.; Lee P.; Engel, J. Jr. Epilepsia,2005, 46, 470.
[2] Auvin, S. Rev. Neurol., 2025, 181, 450.
[3] Springer K.; Varghese N.; Tzingounis, A. V. Dev. Neurosci.,2021, 43, 191.
[4] Wang, H. Science, 1998, 282, 1890.
[5] Wladyka C. L.; Kunze, D. L. J. Physiol.,2006, 575, 175.
[6] Peters H. C.; Hu H.; Pongs O.; Storm J. F.; Isbrandt D. Nat. Neurosci.,2005, 8, 51.
[7] Chen J.; Tao Q.; Fan L.; Shen Y.; Liu J.; Luo H.; Yang Z.; Liang M.; Gan, J. Mol. Genet. Genomic Med.,2022, 10, e2024.
[8] Blackburn-Munro G.; Dalby-Brown W.; Mirza N. R.; Mikkelsen J. D.; Blackburn-Munro, R. E. CNS Drug Rev.,2005, 11, 1.
[9] French J. A.; Porter R. J.; Perucca E.; Brodie M. J.; Rogawski M. A.; Pimstone S.; Aycardi E.; Harden C.; Qian J.; Rosenblut C. L.; Kenney C.; Beatch G. N.; Group, X. T. S. JAMA Neurol.,2023, 80, 1145.
[10] Perucca E.; Taglialatela M. CNS Drugs,2025, 39, 263.
[11] Bialer M.; Johannessen S. I.; Koepp M. J.; Perucca E.; Perucca P.; Tomson T.; White H. S. Epilepsia,2024, 65, 2831.
[12] Zhang Y. M.; Xu H. Y.; Hu H. N.; Tian F. Y.; Chen F.; Liu H. N.; Zhan L.; Pi X. P.; Liu J.; Gao Z. B.; Nan, F. J. J. Med. Chem.,2021, 64, 5816.
[13] Bialer M.; Johannessen S. I.; Koepp M. J.; Perucca E.; Perucca P.; Tomson T.; White H. S. Epilepsia,2024, 65, 2858.
[14] Wei S.; Shiwen W.; Cao-Wenjing C.; Huajun Y.; Qun, W. CNS Neurosci. Ther.,2024, 30, e70002.
[15] Liu Z.; Du L.; Li, M. Curr. Med. Chem.,2012, 19, 1405.
[16] Neyroud N.; Tesson F.; Denjoy I.; Leibovici M.; Donger C.; Barhanin J.; Faure S.; Gary F.; Coumel P.; Petit C.; Schwartz K.; Guicheney P. Nat. Genet.,1997, 15, 186.
[17] Whittaker D. G.; Colman M. A.; Ni H.; Hancox J. C.; Zhang H. Front. Physiol.,2018, 9, 1402.
[18] Chen Y. H.; Xu S. J.; Bendahhou S.; Wang X. L.; Wang Y.; Xu W. Y.; Jin H. W.; Sun H.; Su X. Y.; Zhuang Q. N.; Yang Y. Q.; Li Y. B.; Liu Y.; Xu H. J.; Li X. F.; Ma N.; Mou C. P.; Chen Z.; Barhanin J.; Huang W. Science,2003, 299, 251.
[19] Kharkovets T.; Hardelin J. P.; Safieddine S.; Schweizer M.; El-Amraoui A.; Petit C.; Jentsch, T. J. Proc. Natl. Acad. Sci. U. S. A.,2000, 97, 4333.
[20] Wang L.; Qiao G. H.; Hu H. N.; Gao Z. B.; Nan, F. J. ACS Med. Chem. Lett.,2019, 10, 27.
[21] Musella S.; Carotenuto L.; Iraci N.; Baroli G.; Ciaglia T.; Nappi P.; Basilicata M. G.; Salviati E.; Barrese V.; Vestuto V.; Pignataro G.; Pepe G.; Sommella E.; Di Sarno V.; Manfra M.; Campiglia P.; Gomez-Monterrey I.; Bertamino A.; Taglialatela M.; Ostacolo C.; Miceli, F. J. Med. Chem.,2022, 65, 11340.
[22] Ma D.; Zheng Y.; Li X.; Zhou X.; Yang Z.; Zhang Y.; Wang L.; Zhang W.; Fang J.; Zhao G.; Hou P.; Nan F.; Yang W.; Su N.; Gao Z.; Guo J. Nat. Commun.,2023, 14, 6632.
[23] Zhang S.; Ma D.; Wang K.; Li Y.; Yang Z.; Li X.; Li J.; He J.; Mei L.; Ye Y.; Chen Z.; Shen J.; Hou P.; Guo J.; Zhang Q.; Yang, H. Nat. Chem. Biol.,2024, 20, 847.
[24] Li X.; Zhang Q.; Guo P.; Fu J.; Mei L.; Lv D.; Wang J.; Lai D.; Ye S.; Yang H.; Guo J. Cell Res.,2021, 31, 52.
[25] Golbraikh A.; Tropsha, A. J. Mol. Graphics Modell.,2002, 20, 269.
[26] Roy K.; Mitra, I. Comb. Chem. High Throughput Screening,2011, 14, 450.
[27] Marbán-González A.; Ramírez-Cid V.; Cristóbal-Ramírez A.; Medina-Franco, J. L. Expert Opin. Drug Discovery,2025, 20, 1387.
[28] Gao W.; Coley, C. W. J. Chem. Inf. Model.,2020, 60, 5714.
[29] Lyu J.; Wang S.; Balius T. E.; Singh I.; Levit A.; Moroz Y. S.; O'meara M. J.; Che T.; Algaa E.; Tolmachova K.; Tolmachev A. A.; Shoichet B. K.; Roth B. L.; Irwin J. J. Nature,2019, 566, 224.
[30] Liu R.; Zuo Y.; Zhang Y.; Zhang, J. Chin. J. Org. Chem.,2025, 45, 3075 (in Chinese).
(刘荣, 左应林, 张英俊, 张霁, 有机化学, 2025, 45, 3075.)
[31] Wager T. T.; Hou X.; Verhoest P. R.; Villalobos, A. ACS Chem. Neurosci.,2010, 1, 435.
[32] Hartwig, J. F. Acc. Chem. Res., 2008, 41, 1534.
[33] Meng E. C.; Goddard T. D.; Pettersen E. F.; Couch G. S.; Pearson Z. J.; Morris J. H.; Ferrin, T. E. Protein Sci.,2023, 32, e4792.

基于分子模块组装的新型KCNQ2激动剂设计与合成

Design and Synthesis of Novel KCNQ2 Agonists Based on Molecular Module Assembly

PDF

Supporting Info.

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 11

Recommended Articles

Metrics

Comments

[1]	Jiaqiang Yang, Xurong Zhou, Yangmi Chen, Huixian She. Synthesis and Antibacterial Activities of Osthole Derivatives Containing Phosphonateptide Fragment [J]. Chinese Journal of Organic Chemistry, 2025, 45(4): 1306-1314.
[2]	Xingjun Li, Jiang Wang, Hong Liu. Research Progress on Structural Optimization on the Lipid-Soluble Ingredients of Salvia miltiorrhiza [J]. Chinese Journal of Organic Chemistry, 2023, 43(2): 471-490.
[3]	Lijun Yin, Chaoqun Li, Xiaoxia Wu, Guangsen Xu, Zhiying Li, Yuemao Shen. Synthesis of (E)-N-(4-Styrene) Acrylamides for DNA Topoisomerase IIα Inhibitors and Antitumor Agents [J]. Chinese Journal of Organic Chemistry, 2022, 42(1): 293-301.
[4]	Hu Yuan, Li Zhenyu, Ding Yanjiao, Li Zhiying, Liu Zhiyong, Shen Yuemao. Antitumor and Topoisomerase Ⅱα Inhibitory Activities of 3-Aryl-7-hydroxyquinolines [J]. Chinese Journal of Organic Chemistry, 2019, 39(11): 3230-3236.
[5]	Li Zhiying, Ding Yanjiao, Bu Huagang, Shen Yuemao. Antitumor and DNA Topoisomerase Ⅱα Inhibitory Activity of 6-Substituted-aryl-2-methoxyquinolines [J]. Chin. J. Org. Chem., 2018, 38(12): 3204-3210.
[6]	Gong Chaochao, Tan Hanyi, Zhang Qian. Structure Optimization and Structure-Activity Relationship Study of a Kind of Type II FAK Inhibitors with N-Phenylpyrazole Ureas [J]. Chin. J. Org. Chem., 2018, 38(11): 3086-3093.
[7]	Zhao Fei, Wang Jiang, Ding Xiao, Shu Shuangjie, Liu Hong. Application of Sulfonyl in Drug Design [J]. Chin. J. Org. Chem., 2016, 36(3): 490-501.
[8]	Lü Qiang, Lu Xinting, Dai Ming, Liu Shimeng, Zhu Weihong, Du Pa, Lü Long. Synthesis and Bioactivity of 2-Benzoyl Pyrimidine Derivatives [J]. Chin. J. Org. Chem., 2015, 35(6): 1260-1269.
[9]	Xu Hongjiao, Li Zhenyu, Wang Zhen, Hao Huilin, Lu Chunhua, Zhu Jing, Shen Yuemao. Synthesis and Preliminary Antitumor Activity Evaluation of 17-(5-(Substituted cinnamamido)pentylamino)-17-demethoxygeldan-amycin Derivatives as Potent Hsp90 Inhibitors [J]. Chin. J. Org. Chem., 2015, 35(10): 2125-2134.
[10]	Wang Jiang, Liu Hong. Application of Nitrile in Drug Design [J]. Chin. J. Org. Chem., 2012, 32(9): 1643-1652.
[11]	WANG Jiang, LIU Hong. Fluorine in Medicinal Chemistry [J]. Chin. J. Org. Chem., 2011, 31(11): 1785-1798.